(IVP) An intravenous pyelogram is a radiographic study of the kidney, ureters, and bladder. After the injection or infusion of iodinated contrast materials into the vein, the contrast medium is excreted by the kidneys. Due to the higher density of the dye, contrast filled areas appear white on x-ray images.
IVPs are used to detect tumors, abnormalities, kidney stones, or any obstructions, and to assess renal blood flow. A pyelogram may also be performed with contrast media injection directly through a ureteral or nephrostomy catheter or percutaneously.

See also X-Ray Projection Imaging, Abdomen CT and Urologic Ultrasound.

Isovist® is a nonionic x-ray contrast agent. Isovist® is suitable for intrathecal applications for example CT myelography, cisternography, the evaluation of cerebrospinal fluid (CSF) circulation and for use in other body cavities. Opacification is directly visible after administration of Iotrolan to the spinal subarachnoid space and various open body cavities. Isovist® flows with the CSF through the arachnoid villi into the venous blood.

(mA): 10^-3 ampere. In radiography, the current flow from the cathode to the anode in the x-ray tube is measured in milliampere. This current regulates the radiation intensity emitted by the x-ray tube.

See X-Ray Tube.

Multi-head contrast media injectors offer flexible contrast media management, simplified workflows and increased patient safety.
Contrast delivery is much more controlled and efficient when using a dual-head CT power injector. These medical devices are needed to enable the short imaging times typical of multidetector computed tomography (CT) scanners.
Triple-head injectors allow selection of a second contrast agent when two different contrast agents are used, or switching to full contrast agent containers when two identical contrast agents are used.

See also Contrast Media Injector, Syringeless CT Power Injector, Single-Head Contrast Media Injector, CT Power Injector.

(MPI) The myocardial perfusion scan is the most common nuclear medicine procedure in cardiac imaging and allows assessing the blood-flow patterns to the heart muscles. The comparison of the radiopharmaceutical distribution after stress and at rest provides information on myocardial viability and cardiac perfusion abnormalities. ECG-gated myocardial perfusion imaging allows the assessment of global and regional myocardial function such as wall motion abnormalities.
The diagnostic accuracy of myocardial perfusion scintigraphy (also abbreviated MPS) allows reliable risk stratification and guides the selection of patients for further interventions, such as revascularization. MPI also has particular advantages over alternative techniques in the management of a number of patient subgroups, including women, the elderly, and those with diabetes. The use of this type of cardiac scintigraphy is associated with greater cost effectiveness of treatment, in terms of life-years saved, particularly in these special patient groups.
Myocardial perfusion scintigrams are acquired with a gamma camera. Single photon emission computed tomography (SPECT) is preferred over planar imaging because of the three dimensional nature of the images and their superior contrast resolution.
Common MPI radiopharmaceuticals, approved by the U.S. Food and Drug Administration (FDA) include: Tl-201 and the Tc-99m-labeled radiopharmaceuticals, such as sestamibi, tetrofosmin, and teboroxime for single-photon imaging. Rb-82 is used for positron emission tomography (PET) imaging.

See also Gated Blood Pool Scintigraphy, Myocardial Late Enhancement, Cardiac MRI and Echocardiography.